The burgeoning field of proximity-inducing modalities has revolutionized antiviral agent development by harnessing the power of molecular proximity to regulate protein-protein or protein-RNA interactions.This review d...The burgeoning field of proximity-inducing modalities has revolutionized antiviral agent development by harnessing the power of molecular proximity to regulate protein-protein or protein-RNA interactions.This review delves into the innovative strategies and breakthroughs in designing antiviral compounds that leverage induced spatial association,a concept with profound implications for both therapeutic applications and fundamental research.We highlight the role of bifunctional molecules in modulating cellular processes to combat viral infections,underscoring their potential within the proximity induction framework.The review encompasses a comprehensive analysis of current applications and future prospects of proximity-inducing molecules in antiviral research,emphasizing their promise for advancing antiviral therapies and infection control strategies.展开更多
HIV remains a global health challenge,and research efforts directed towards a functional cure require people living with HIV(PLHIV)in-volvement in clinical trials.Our study assessed willingness to participate in HIV f...HIV remains a global health challenge,and research efforts directed towards a functional cure require people living with HIV(PLHIV)in-volvement in clinical trials.Our study assessed willingness to participate in HIV functional cure–related clinical trials and associated factors among PLHIV in Guangzhou,China,using a questionnaire survey approach.We analyzed responses from 718 questionnaires,finding that 71.2%were willing to participate in Phase Ⅲtrials,while 51.7%were willing to participate in Phase I trials and 42.9%expressed acceptability for analytic treatment interruption.Multivariate logistic regression demonstrated that male PLHIV,those with awareness of functional cure,and PLHIV,who had been on antiretroviral therapy(ART)for less than 1 year,were more willing to partic-ipate in Phase Ⅲtrials.Those with a body mass index greater than 24,and those without resistance to ART drug were more willing to participate in Phase I trials.The major motivations for participation in Phase Ⅲtrials were access to cutting-edge treatments(62.6%)and supporting research(55.3%).Safety was the main concern contributing to hesitancy.Our study revealed a high willingness to participate in HIV functional cure–related trials among PLHIV in Guangzhou,China,and willingness varied across different trial phases and was influenced by multiple factors.This study provides valuable references for future clinical trial recruitment strategies and public health policy formulation.展开更多
基金supported by the Key Research and Development Program,Ministry of Science and Technology of China(2023YFC2606500)the Shandong Laboratory Program(SYS202205)+1 种基金the China Postdoctoral Science Foundation(2024M761823)supported by the Korea Health Industry Development Institute(KHIDI)funded by the Ministry of Health&Welfare,Republic of Korea(HI22C2067 to Meehyein Kim)。
文摘The burgeoning field of proximity-inducing modalities has revolutionized antiviral agent development by harnessing the power of molecular proximity to regulate protein-protein or protein-RNA interactions.This review delves into the innovative strategies and breakthroughs in designing antiviral compounds that leverage induced spatial association,a concept with profound implications for both therapeutic applications and fundamental research.We highlight the role of bifunctional molecules in modulating cellular processes to combat viral infections,underscoring their potential within the proximity induction framework.The review encompasses a comprehensive analysis of current applications and future prospects of proximity-inducing molecules in antiviral research,emphasizing their promise for advancing antiviral therapies and infection control strategies.
基金supported by the National Natural Science Foundation of China(82271786 and 81971927)the Science and Technology Planning Project of Shenzhen City(JSGG20200225152008136 and JCYJ20190807155009482)+2 种基金the Science and Technology Planning Project of Guangdong Province(2021B1212040017)Sanming Project of Medicine in Shenzhen Nanshan(SZSM202103008)the Key Subject of Nanshan district of Shenzhen for AIDS surveillance and prevention.
文摘HIV remains a global health challenge,and research efforts directed towards a functional cure require people living with HIV(PLHIV)in-volvement in clinical trials.Our study assessed willingness to participate in HIV functional cure–related clinical trials and associated factors among PLHIV in Guangzhou,China,using a questionnaire survey approach.We analyzed responses from 718 questionnaires,finding that 71.2%were willing to participate in Phase Ⅲtrials,while 51.7%were willing to participate in Phase I trials and 42.9%expressed acceptability for analytic treatment interruption.Multivariate logistic regression demonstrated that male PLHIV,those with awareness of functional cure,and PLHIV,who had been on antiretroviral therapy(ART)for less than 1 year,were more willing to partic-ipate in Phase Ⅲtrials.Those with a body mass index greater than 24,and those without resistance to ART drug were more willing to participate in Phase I trials.The major motivations for participation in Phase Ⅲtrials were access to cutting-edge treatments(62.6%)and supporting research(55.3%).Safety was the main concern contributing to hesitancy.Our study revealed a high willingness to participate in HIV functional cure–related trials among PLHIV in Guangzhou,China,and willingness varied across different trial phases and was influenced by multiple factors.This study provides valuable references for future clinical trial recruitment strategies and public health policy formulation.
